Teva Pharmaceutical Industries Ltd. $TEVA Stock Holdings Lifted by Phoenix Financial Ltd.

Phoenix Financial Ltd. increased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 9.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 41,295,244 shares of the company’s stock after buying an additional 3,533,800 shares during the period. Teva Pharmaceutical Industries accounts for 11.0% of Phoenix Financial Ltd.’s portfolio, making the stock its largest holding. Phoenix Financial Ltd.’s holdings in Teva Pharmaceutical Industries were worth $834,164,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. AQR Capital Management LLC lifted its stake in shares of Teva Pharmaceutical Industries by 24.6% in the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after buying an additional 4,732 shares during the last quarter. Focus Partners Wealth increased its stake in Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after acquiring an additional 1,739 shares during the period. GAMMA Investing LLC increased its position in shares of Teva Pharmaceutical Industries by 65.9% during the second quarter. GAMMA Investing LLC now owns 7,282 shares of the company’s stock valued at $122,000 after purchasing an additional 2,892 shares during the period. Fifth Third Bancorp increased its holdings in Teva Pharmaceutical Industries by 49.2% in the 2nd quarter. Fifth Third Bancorp now owns 32,805 shares of the company’s stock valued at $550,000 after buying an additional 10,820 shares during the period. Finally, Hartford Investment Management Co. raised its position in Teva Pharmaceutical Industries by 30.9% in the second quarter. Hartford Investment Management Co. now owns 13,796 shares of the company’s stock worth $231,000 after purchasing an additional 3,257 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $32.11 on Tuesday. The company has a market cap of $36.83 billion, a P/E ratio of 53.52, a P/E/G ratio of 1.82 and a beta of 0.66. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $33.42. The stock’s 50-day simple moving average is $29.79 and its 200 day simple moving average is $22.78. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. The Goldman Sachs Group lifted their target price on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Piper Sandler boosted their price target on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, December 22nd. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Sunday, January 18th. Finally, Scotiabank started coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Buy” and a consensus price target of $33.67.

Insider Activity

In other news, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the transaction, the insider directly owned 52,828 shares in the company, valued at approximately $1,517,748.44. The trade was a 80.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the transaction, the vice president directly owned 48,384 shares in the company, valued at $1,387,653.12. The trade was a 70.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 622,060 shares of company stock valued at $17,076,965 over the last quarter. 0.49% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.